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SYNOPSIS
The thesis entitled, “Design, Synthesis and Anticancer Evaluation of DNA Interactive Pyrrolo[2,1-c][1,4]benzodiazepine Hybrids, Chrysin Conjugates and Preparation of some Bioactive Heterocycles” has been divided into four chapters. Chapter I gives the general introduction about cancer chemotherapy, covalent, and non-covalent interactions of drug-DNA, particularly of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour antibiotics, flavone derivatives, the use of NaI/AcOH in organic synthesis and the objectives of the present work. Chapter II comprises of three sections; section A consists of the design, synthesis and DNA binding affinity of novel chrysin-pyrrolo[2,1-c][1,4]benzodiazepine hybrids and their activity. While section B consists of the design, synthesis and DNA binding affinity of novel quinazolinone-PBD hybrids and their activity on nine human tumour cell lines. The section C deals with the design synthesis and DNA binding affinity of novel indolindione-PBD hybrids. Chapter III comprises of the design, synthesis and in vitro anticancer activity of novel chrysin conjugates on sixty human tumour cell lines. Chapter IV describes the application of sodium iodide-acetic acid reagent system for the synthesis of various bioactive heterocycles through azidoreductive cyclocondensation process.

Chapter I: General Introduction

	Cancer is a disease caused by the malfunctioning of normal cells.  Chemotherapy or the use of chemical agents to destroy the cancer cells is a mainstay in the treatment of malignancies. A major advantage of chemotherapy is its ability to treat widespread or metastatic cancer, whereas surgery and radiation therapies are limited to treating the cancers that are confined to specific area. The major categories of chemotherapeutic agents are antitumour antibiotics, topoisomerase I and II inhibitors, DNA interactive agents and other miscellaneous compounds. The first PBD antitumour antibiotic anthramycin has been described by Leimgruber et. al., about 38 years back, and since then a number of compounds have been developed on PBDs leading to DNA binding ligands. Pyrrolo[2,1-c][1,4]benzodiazepines have the potential as regulators of gene expression with possible therapeutic application in the treatment of genetic disorders, including cancer.
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are well known class  of antitumour antibiotics with sequence selective DNA binding ability that are derived from various Streptomyces species. Their mode of interaction with DNA has been extensively studied and it is considered unique as they bind within the minor groove of B form DNA. These compounds exert their biological activity by covalently binding to the C2-amino group of guanine residue in the minor groove of DNA through the imine or imine equivalent functionality at N10-C11 of PBD moiety. 
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Certain plant species containing flavonoids have been widely used in traditional eastern medicine to treat cancer. Actually, some flavonoids such as baicalain and its glycosides have been clinically used in China for many years. However, Western medicine has not yet used flavonoids therapeutically. Attempts are under way to produce new flavonoid derivatives with less toxic effects.
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Chrysin, a flavonoid derivative is generally non toxic; it can be used in combination with toxic drugs that nowadays are used in cancer therapy in order to reduce their toxic effects. Although certain studies show that chrysin possesses synergic effect with other drugs, it was found that it can be used in combination with topoisomerase poisons or intercalators in order to improve their anticancer properties.  
Figure-4 	Recent developments in organic synthetic methodologies have witnessed the emergence of a diverse number of iodine compounds, which have been utilized successfully in achieving a multitude of chemical transformations in high yields. Sodium iodide-acetic acid reagent system has been widely employed towards the synthesis of various bioactive heterocycles. 
Chapter II-Section A: Design, synthesis, DNA binding affinity and in vitro cytotoxicity of novel chrysin-pyrrolo[2,1-c][1,4]benzodiazepine hybrids
	Recently, there has been growing interest in modifying and extending the recognition patterns of DNA binding ligands. Pyrrolo[2,1-c][1,4]benzodiazepine antitumour antibiotics bind covalently to the N2 of guanine in the minor groove of DNA. In the past few years several PBD analogues have been designed and synthesized with the aim of finding related compounds showing better antitumour activity. The PBDs have been used as novel scaffolds to attach EDTA, epoxide, (+)-cyclopropapyrroloindole and cyclopropylbenzindole moieties leading to novel unsymmetrical hybrids of PBD, which have exhibited novel sequence selective DNA cleaving and cross-linking properties. Chrysin on the other hand represent an important class of compounds that interact with DNA either by DNA intercalation or topoisomerase inhibition. 
The objective of the present work is to combine the features of both DNA intercalating and DNA covalent binding properties in the same molecule. Therefore in this design, chrysin has been linked to the PBD through its C8 position. In this section the synthesis, DNA binding affinity and in vitro cytotoxicity of these new chrysin-PBD hybrids have been described.  
The precursor 2S-N-[(n-bromoalkyloxy)-5-methoxy-2-nitrobenzoyl]-pyrrolidine-2-carboxaldehyde diethyl thioacetal 7a-c has been prepared by employing commercially available vanillin. Oxidation of vanillin followed by esterification by literature method provides vanillin methyl ester 3. This on coupling with various n-bromoalkanes gives 4a-c which upon nitration followed by ester hydrolysis affords 6a-c. (2S)-Pyrrolidine-2-carboxaldehyde diethylthioacetal has been coupled to 6a-c to produce the nitrothioacetal precursor 7a-c. These have been coupled with chrysin to give 8a-c. These nitrothioacetals 8a-c upon reduction with SnCl2.2H2O gives 9a-c, the deprotection of diethyl thioacetal group afforded the desired compounds 10a-c (Scheme 1).    











Scheme 1

The DNA binding ability for these chrysin-PBD hybrids have been compared with Tm of DC-81. It is interesting to observe that all the three compounds elevate the helix melting temperature of CT-DNA after incubation for 18 h at 37 C. In this assay, compound 10a elevates the melting temperature to 8.8 C. Compound 10b elevates the melting temperature to 7.3 C, while the compound 10c elevated the melting temperature to 6.7 C, whereas DC-81 exhibits aTm of 0.7 C after incubation under similar conditions. Thus, this demonstrated that this class of PBD hybrids posses significant DNA binding ability. The restriction endonuclease inhibition studies carried out on these molecules also confirm the relative binding affinity of these new PBD hybrids.
Compounds 10a and 10c have been evaluated for their in vitro cytotoxicity in selected human cancer cell lines of colon (Colo205), lung (Hop-62),  cervix (SiHa), prostate (DU145, PC3), oral (DWD, HT1080), and breast (MCF7, Zr-75-1)   origin. These compounds exhibited more than 20% growth inhibition at g/mL concentration on these cell lines. Compounds 10a and 10c suppress MCF7 cell growth by 40% and 37%. They also suppress the Zr-15-1 cell growth by 22% and HT1080 cell growth by 30% and 26%. 

Chapter II-Section B: Design, synthesis and biological evaluation of novel quinazolinone-pyrrolo[2,1-c][1,4]benzodiazepine hybrids 

Quinazolinone based compounds are well known for their broad spectrum of biological activities, the most important among them being the anticancer activity. The anticancer activity of these compounds has been extensively studied, although the mechanism of action is not known, most of the quinazolinones exert their antitumour activity either by tubulin inhibition or PARP inhibition or as alkylating agents.
In view of the importance of these quinazolinone derivatives for their anticancer potential, it has been considered of interest to synthesize new quinazolinone moieties that have been linked to the PBD ring system to evaluate their DNA binding affinity and in vitro cytotoxicity. 
Synthesis of these novel quinazolinone-PBD hybrids have been carried out by employing substituted quinazolinones 12a-b as the precursors, which have been obtained by the reaction of substituted 2-aminobenzophenone 11a-b with chlorosulfonyl isocyanate to yield substituted quinazolinone 12a-b. These were further treated with the appropriate n-bromo alkane to obtain the desired intermediates 13a-c and 14a-c (Scheme 2).
Scheme 2.  
The other precursor (2S)-N-(4-hydroxy-5-methoxy-2-nitrobenzoyl) pyrrolodine-2-carboxaldehyde diethyl thioacetal 21 has been prepared by employing commercially available vanillin. Oxidation of vanillin followed by esterification by literature method provides vanillin methyl ester 3. This on benzylation gives 15, which upon nitration followed by ester hydrolysis affords 17. L-Proline methyl ester has been coupled to 17 to give the nitro ester 18. This nitro ester on treatment with DIBAL-H followed by protection of aldehyde 19 with ethanethiol gives diethyl thioacetal 20. This upon debenzylation with BF3.OEt2 provides compound 21. This nitro thioacetal has been coupled with the corresponding substituted quinazolinones 13a-c and 14a-c to give 22a-c and 23a-c. These nitrothioacetals 22a-c and 23a-c have been reduced with SnCl2.2H2O to give 24a-c and 25a-c. The deprotection of the diethyl thioacetal group afforded the desired products 26a-c and 27a-c (Scheme 3).  
Scheme 3

Compounds 26a and 26c have been evaluated for their in vitro cytotoxicity in selected human cancer cell lines of colon (Colo205), lung (Hop-62), cervix (SiHa), prostate (DU145, PC3), oral (DWD, HT1080), and breast (MCF7, Zr-75-1)   origin. These compounds have exhibited more than 80% growth inhibition at g/mL concentration in some cell lines. Compounds 26a and 26c suppress Colon 205 cell growth by 92% and 85%, DU145 cell growth by 92% and 90%, DWD cell growth by 95%, Hop62 cell growth by 94% and 95%, HT1080 cell growth by 91% and 92%, MCF7 cell growth by 88% and 92% and PC3 cell growth by 89% and 93%. They are known for suppressing the SiHa cell growth by 84% and Zr-25-1 cell growth by 92% respectively. 
The DNA binding ability for these quinazolinone-PBD hybrids have been compared with Tm of DC-81. It is interesting to observe that in this assay the compounds elevate the helix melting temperature of CT-DNA upto 1.3 C for compound 26a, 1.6 C for compound 26b, 2.3 C for compound 26c, 0.8 C for compound 27b and 1.0 C for compound 27c after incubation for 18 h at 37 C, whereas DC-81 exhibits a Tm of 0.7 C after incubation under similar conditions. The compound 27a has shown a Tm of 0.5 C and the dichloro substituted quinazolinones linked PBDs have shown less DNA binding affinity than their monochloro substituted analogues. This variation might be due to the presence of bulky chloro groups in case of the later compounds. As the spacer length is increased the DNA binding affinity of these compounds is also enhanced. 

Chapter II-Section C: Design, synthesis and DNA binding affinity of novel indolindione-PBD hybrids

Indolindione ring systems when coupled to various bioactive heterocycles have drastically increased the activities of the heterocycles due to the antiproliferative and alkylating properties. The derivatives of these compounds have also exhibited promising anticancer activities on various cell lines.
In the present work it has been envisaged to link these indolindiones to the PBDs with a view to combine the alkylating properties of PBDs with alkylating and antiproliferative properties of indolindiones and to study their DNA binding affinity. These compounds are under the process of evaluation of their in vitro cytotoxicity. 

Synthesis of these novel indolindione-PBD hybrids has been carried out by employing 1-(n-bromoalkyl)-2,3-indolinedione 29a-c as one of the precursors, which has been  obtained by the reaction of 2,3-indolindione 28 with appropriate n-bromo alkane to obtain the desired intermediates, which are coupled with (2S)-N-(4-hydroxy-5-methoxy-2-nitrobenzoyl)pyrrolodine-2-carboxaldehyde diethyl thioacetal 21 to give 30a-c. This nitrothioacetal 30a-c has been reduced with SnCl2.2H2O and on deprotection of the thioacetal group afforded the desired products 31a-c (Scheme 4).













Scheme 4

 
The DNA binding ability for the indolindione-PBD hybrids have been compared with Tm of DC-81. It is interesting to observe that in this assay the compounds 31a, 31b and 31c elevate the helix melting temperature of CT-DNA upto 1.2 C, 1.0 C, 0.9 C  respectively after incubation for 18 h at 37 C, whereas DC-81 exhibits a Tm of 0.7 C after incubation under similar conditions. Thus demonstrating that these PBD hybrids possess moderate DNA binding ability.



Chapter III: Design, synthesis and in vitro cytotoxicity of novel chrysin conjugates

Naturally occurring chrysin has attracted the attention of medicinal chemists due to its ability to exhibit cytotoxicity by interacting with the DNA either by intercalation between the DNA base pairs or by inhibiting topoisomerase II. Although many new analogues of chrysin have been designed and synthesized, none of them have reached the clinical trails. In order to enhance the anticancer properties of chrysin, various conjugates have been designed, synthesized and evaluated for their anticancer activity on a number of cell lines. 
In this part of the work, synthesis of various types of chrysin conjugates by linking them to other anticancer moieties that can interact with DNA have been envisaged. A variety of chrysin conjugates with alkyl and piperazinylalkyl spacers and anticancer heterocylces like the coumarins, anthraquinones and chrysin dimers have been synthesized and evaluated for their anticancer potential on various human tumor cell lines.  
	The synthesis of novel C7 linked aminoalkyl chrysin derivatives 39a-c, 40a-c and 41a-c has been carried out by employing phloroglucinol 32 as the starting material, which is treated with methyl iodide in presence potassium carbonate to give dimethoxy phenol 33. This compound is further acetylated to give the corresponding acetophenone 34, which upon aldol condensation with benzaldehyde gives the chalcone 35. This is cyclized using iodine in DMSO and demethylated with BBr3 to give chrysin 37, which is further refluxed in acetone with the corresponding dibromo alkanes and potassium carbonate to yield the compounds 38a-c. This is further refluxed with corresponding amino alkyl base in acetonitrile in presence of potassium carbonate to yield the desired products (Scheme 5).   

Scheme 5


The precursors, alkylbromo linked piperazinyl coumarins, have been synthesized by employing 2-hydroxy acetophenone 42 as the starting material, which is cyclized to give hydroxy coumarin 43. This upon treatment with piperazine yields the piperazinyl coumarin 44. This is refluxed with dibromo alkane in acetonitrile in presence of potassium carbonate to give the desired precursors 45a-c. This upon further treatment with chrysin yields the corresponding products 46a-c (Scheme 6).

Scheme 6




Synthesis of novel anthraquinone chrysin conjugates has been carried out by employing N1-(9,10-dioxo-9,10-dihydro-1-anthracenyl)-n-bromoalkanamide 48a-b as  precursors, that have been obtained by the reaction of an appropriate acid chloride with 1-amino anthraquinone 47 (Scheme 7).  




Scheme 7

The compounds 49a-b have been prepared by refluxing the precursor N1-(9,10-dioxo-9,10-dihydro-1-anthracenyl)-n-bromoalkanamide 48a-b along with chrysin 37 and potassium carbonate in acetone (Scheme 8).

Scheme 8


5-Hydroxy-7-n-[(5-hydroxy-4-oxo-2-phenyl-4H-7-chromenyl)oxy]alkoxy-2-phenyl-4H-4-chromenone 50a-c have been prepared by refluxing chrysin 37 with the corresponding dibromo alkanes (Scheme 9).





Scheme 9 


5-Hydroxy-7-[n-(4-n-[(5-hydroxy-4-oxo-2-phenyl-4H-7-chromenyl)oxy] alkylpiperazino)alkoxy]-2-phenyl-4H-4-chromenones 51a-c have been prepared by treating 7-[(n-bromoalkyl)oxy]-5-hydroxy-2-phenyl-4H-4-chromenone 38a-c with piperazine (Scheme 10). 

Scheme 10

The above novel chrysin conjugates have been initially screened for their in vitro cytotoxicity on three human tumor cell lines comprising of MCF7 (breast), NCI-H460 (lung) and SF-268 (CNS). The compounds 39a, 39c, 40a, 40c, 41a, 46a which have shown 0% cell growth have been selected for further evaluated in the standard NCI 60 cell line panel. The compounds  have shown to possess less than 10 nanomolar potency (at the LC50 level) against nine cell lines of one non-small-cell lung cancer cell line (NCI-H522), one CNS cancer cell line (SF-539), three melanoma cancer cell lines (SK-MEL-2, SK-MEL-5, UACC-62 and M14) two renal cancer cell lines (A 498 and RXF 393) and one breast cancer cell line (MDA-MB-435). Interestingly, these compounds possess selective anticancer activity.  
Chapter IV: NaI-AcOH: A versatile reagent system in organic synthesis

Sodium iodide in combination with various other organic, inorganic reagents and solvents has been extensively used for different chemical transformations in high yields.
In view of the importance of sodium iodide in organic synthesis a new reagent system i.e., a combination of sodium iodide and acetic acid has been developed and employed towards the synthesis of various bioactive heterocycles by azidoreductive cyclocondensation process as discussed below. Sodium iodide in combination with organic acids (acetic acid, formic acid) has also been employed for the N-acylation of aromatic azides. 
The commercially available substituted anthranillic acid was treated with sodium acetate, sodium nitrite and sodium azide to yield the substituted 2-azidobenoic acid 53a-c, upon treatment with the corresponding lactams provide N-(2-azidobenzoyl)-lactams 54a-i. These compounds are further treated with sodium iodide in acetic acid (Scheme 11) to yield the corresponding fused[2,1-b] quinazolinones 55a-i. 
Scheme 11.

Further, N-substituted imides have been synthesized by the reductive cyclocondensation process by the treatment the corresponding anhydrides or acids with the respective azides (Scheme 12) in presence of sodium iodide in acetic acid.

Scheme 12. 


DNA intercalating naphthalimide dimers linked by alkyl spacers and piperazinyl alkyl spacers have been synthesized by refluxing the naphthalic anhydride or naphthalic acid and the respective diazide in presence of sodium iodide in acetic acid (Scheme 13) until the TLC indicated the completion of the reaction. The products were obtained in good to moderate yields.









Scheme 13


	Quinazolindione derivatives 64a-e have been synthesized in good yields from the isatoic anhydride 63 and the corresponding azide (Scheme 14).
Scheme 14


Naphthalimide linked PBD-5,11-diones have been synthesized by employing compounds 65a-c as the starting materials. This nitro precursor upon treating with sodium azide in HMPA at room temperature produces 66a-c. The azido compounds 66a-c upon heating in presence of sodium azide and DMSO yield 67a-c. These upon reductive cyclocondensation in one pot afford the desired products 68a-c in good yields (Scheme 15). 
Scheme 15

Sodium iodide in presence of the organic acids namely, acetic acid or formic acid has been employed towards the reduction of azides to their corresponding acetamides or formamides (Scheme 16). The products were obtained in good to moderate yields. 
Scheme 16
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